Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted

Dow Jones

Oct 28, 2025

By Rob Curran

Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services.

The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier.

Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet.

Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet.

Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50.

The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts.

Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 28, 2025 07:15 ET (11:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578958021"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578958021\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578958021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578958021","market":"us","top_or_hot":-1,"title":"Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n</p>\n<p>\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n</p>\n<p>\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n</p>\n<p>\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n</p>\n<p>\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:15 ET (11:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 19:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n</p>\n<p>\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n</p>\n<p>\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n</p>\n<p>\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n</p>\n<p>\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:15 ET (11:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578958021","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578958021","pubTimestamp":1761650100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services.The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier.Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet.Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet.Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50.The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts.Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4196":"保健护理服务","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LH":"徕博科","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD"},"translate_title":"Labcorp第三季度净利润、收入增长，2025年调整后每股收益预期增强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n\n\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n\n\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n\n\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n\n\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n\n\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n\n\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 07:15 ET (11:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}